O&G Vivas · Gynaecological oncology — vulvar cancer and VIN
Vulvar cancer on lichen sclerosus with a focal ulcer — structured oral station (12 minutes)
FRANZCOG oral-format station on vulvar squamous cell carcinoma arising on lichen sclerosus: the candidate defends the FIGO 2021 staging (Stage IB) and depth-of-invasion definition, sentinel node biopsy as the standard with the GROINSS-V 2.5 percent groin recurrence, the lymphoedema morbidity data, and the two VIN pathways (usual HPV vs differentiated lichen sclerosus). Scored against the eight published RANZCOG oral domains.
On this page & tools
Target exams
Station format
4 minutes reading, 12 minutes examination, 20 marks, global scoring. The eight published RANZCOG oral domains apply to every station: history and examination; investigations and interpreting results; treatment and management; clinical knowledge; complex, urgent or unusual clinical presentations; rapport with patient, support person or colleague; respect; communication skills. You are marked on how you behave, not only what you know. [1]
Reveal the examiner script and model responses
Opening prompt — "Stage this lesion and explain your reasoning."
Model response — the FIGO 2021 stage: [1]
- "This is Stage IB vulvar squamous cell carcinoma. Stage IB is a tumour over 2 cm in size or with stromal invasion over 1 mm, confined to the vulva with negative nodes. This tumour is 2.5 cm with 4 mm of invasion."
- "Depth of invasion in the 2021 system is measured from the basement membrane of the deepest adjacent dysplastic, tumour-free rete ridge to the deepest point of invasion — a change from the older dermal-papilla method."[1]
Probe 1 — "Describe the surgical management of the primary tumour and the groin."
- "The primary tumour is managed by wide local excision (radical local excision) with a 1 to 2 cm margin through healthy tissue to the deep fascia. Radical vulvectomy is reserved for large, multifocal or locally advanced disease." [1]
- "The groin is managed by sentinel lymph node biopsy — the standard for early-stage, unifocal, node-negative disease. Because this lesion is lateralised on the right labium majus, over 1 cm from the midline, ipsilateral sentinel biopsy suffices; inguinofemoral lymphadenectomy is performed only if the sentinel node is positive." [2]
Probe 2 — "Reproduce the GROINSS-V evidence for sentinel node biopsy."
- "GROINSS-V enrolled 377 women with unifocal T1 squamous cell carcinoma under 4 cm who underwent the sentinel node procedure, with inguinofemoral lymphadenectomy only for sentinel metastases." [2]
- "At a median follow-up of 105 months, the isolated groin recurrence rate was 2.5 percent at 5 years for sentinel-node-negative patients, and disease-specific 10-year survival was 91 percent for sentinel-negative versus 65 percent for sentinel-positive. This is the safety evidence that made sentinel biopsy the standard." [2]
Probe 3 — "What is the morbidity argument for sentinel biopsy over full lymphadenectomy?"
- "Per the Rahm 2022 population-based study, persisting lymphoedema is about 4 percent after sentinel biopsy versus about 39 percent after inguinofemoral lymphadenectomy; infection about 15 percent versus about 36 percent." [4]
- "Lymphoedema is near-ubiquitous when adjuvant groin radiotherapy follows a full lymphadenectomy — the double hit. Sentinel biopsy avoids both." [4]
Probe 4 — Contrast: "How does this relate to VIN, and to the lichen sclerosus?"
- "This tumour arose on lichen sclerosus via the HPV-independent pathway — differentiated VIN, keratinising SCC, older women. The other pathway is HPV-associated: usual-type VIN (warty/basaloid), basaloid SCC, younger women." [1][3]
- "VIN is managed by the 3-step approach: biopsy to exclude invasion; treat (excision, laser, imiquimod for usual type); surveil and treat the lichen sclerosus with ultrapotent corticosteroid. Differentiated VIN demands excision because of its high invasive potential." [3]
Probe 5 — Communication: "How do you explain the plan to this woman?"
- "I would say: 'The biopsy confirms a skin cancer on the vulva — a squamous cell carcinoma — that has arisen on your lichen sclerosus. The good news is that it is small and the lymph nodes feel normal. I will remove it with a margin of healthy skin, and check the lymph glands on that side with a tracer test called a sentinel node biopsy — this is far gentler than removing all the glands. If that node is clear, we will not need to remove more glands. We will also treat your lichen sclerosus with a strong ointment to lower the chance of this coming back, and see you regularly for the long term.' "[1][3]
You have read the opening of this viva. The complete unit — every section and its primary-source references — is part of the Obstetrics & Gynaecology fellowship atlas.
References4Show ledgerHide ledger
- [1]Olawaiye AB, Cotler J, Cuello MA, Bhatla N, Okamoto A, Wilailak S, et al. FIGO staging for carcinoma of the vulva: 2021 revision. Int J Gynaecol Obstet, 2021.PMID 34520062
- [2]Te Grootenhuis NC, van der Zee AG, van Doorn HC, van der Velden J, Vergote I, Zanagnolo V, et al. Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I. Gynecol Oncol, 2016.PMID 26428940
- [3]Sideri M, Jones RW, Wilkinson EJ, Preti M, Heller DS, Scurry J, et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J Reprod Med, 2005.PMID 16419625
- [4]Rahm C, Adok C, Dahm-Kähler P, Bohlin KS Complications and risk factors in vulvar cancer surgery - A population-based study. Eur J Surg Oncol, 2022.PMID 35148915